Stocks · News reference
FDA accepts Sarepta's filings seeking traditional approval for AMONDYS 45 and VYONDYS 53, with a decision expected by February 2027.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.26 by 146.15 percent. This is a 68.32 percent decrease over earnings of $2.02 per share
Filed: 2026-07-27 AccNo: 0001193125-26-316995 Size: 334 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026.